Previous 10 | Next 10 |
Image source: The Motley Fool. Agenus (NASDAQ: AGEN) Q2 2022 Earnings Call Aug 09, 2022 , 8:30 a.m. ET Operator Continue reading For further details see: Agenus (AGEN) Q2 2022 Earnings Call Transcript
Agenus Inc. (AGEN) Q2 2022 Earnings Conference Call August 09, 2022 08:30 AM ET Company Participants Ethan Lovell - Chief of External Affairs & Communications Officer Garo Armen - Chairman & Chief Executive Officer Christine Klaskin - Vice President-Finan...
Agenus press release ( NASDAQ: AGEN ): Q2 GAAP EPS of -$0.17. Revenue of $20.93M (+95.1% Y/Y). The company ended second quarter 2022 with a cash and short-term investment balance of $238 million as compared to $263 million and $307 million on March 31, 2022, and Decemb...
Botensilimab (Fc-enhanced CTLA-4)/balstilimab (PD-1) combination data presented at the 2022 ESMO World GI Congress demonstrated remarkable clinical activity in microsatellite stable colorectal cancer (MSS CRC) Agenus expects to present additional botensilimab expansion cohort data at ...
Agenus ( NASDAQ: AGEN ) is scheduled to announce Q2 earnings results on Tuesday, August 9th, before market open. The consensus EPS Estimate is -$0.22 (+40.5% Y/Y) and the consensus Revenue Estimate is $18.7M (+74.3% Y/Y). Over the last 3 months, EPS estimates have seen...
LEXINGTON, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced the Company will attend the BTIG Biotechnology Conference....
Study will evaluate safety and tolerability of AGEN1571 as a single agent and in combination with botensilimab and balstilimab Preclinical data support best-in-class potential of AGEN1571 LEXINGTON, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq: AGEN), an im...
LEXINGTON, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN) an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced it will release its second quarter 2022 financial results befor...
Agenus (NASDAQ: AGEN) opened at $2.65 then rose to a high of $2.93 in the early afternoon. The stock has a 52-week low of $1.25 and a 52-week high of $6.79. The pharmaceutical company focuses on finding therapies to treat cancer and infections by activating the body's immune respons...
It can be a lot of fun buying stocks trading in the single digits. While there are a lot of bad companies down in the cheap seats, sometimes you can find some amazing bargains. Our roundtable has found three really cool biotech stocks trading under $10 a share. Here's why we like SeaS...
News, Short Squeeze, Breakout and More Instantly...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immunology-based therapies for cancer, received notice from NASDAQ on April 30, 2024, that the Company has regained compliance with the $1.00 minimum bid price requirement set forth in NASDAQ Listing Rule 5550(a)(2). Accordingly, th...
2024-04-28 08:30:00 ET Last Friday, Agenus (NASDAQ: AGEN) , an immuno-oncology player, saw its shares soar by a staggering 40.8%. This remarkable rally occurred seemingly without a clear catalyst. The company is set to announce its first-quarter earnings for 2024 before the market o...
A look at the top 10 most actives in the United States Pineapple Energy Inc. (PEGY) rose 20.6% to $0.0626 on volume of 316,091,551 shares Snap Inc. Class A (SNAP) rose 27.6% to $14.55 on volume of 158,621,648 shares PROSHARES TRUST (SQQQ) fell 4.8% to $11.43 on volume of 135,432,504 share...